Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRisk of high-grade skin rash in cancer patients treated with cetuximab – an antibody against epidermal growth factor receptor: systemic review and meta-analysis
Oncology (Karger), 07/23/09
Su X et al. - In a study to quantify the overall incidence and risk of severe skin rash in cancer pts treated with cetuximab, it was reported that cancer pts who received cetuximab have a substantial risk of developing high-grade skin rash. The risk may be particularly increased in pts with colorectal cancer (CRC).
Methods- Databases Medline (OVID 1998 to July 2008), Web of Science, and abstracts presented at the American Society of Clinical Oncology conferences from 2004 through July 2008 were searched to identify relevant studies.
- Eligible studies include phase II and III clinical trials in which pts were treated with a single agent, ie, cetuximab at 400 mg/m2 as initial dose followed by 250 mg/m2 wkly.
- Incidence, relative risk (RR), and 95% confidence intervals (CI) were calculated using a fixed-effects or random-effects model based on the heterogeneity of included studies.
- 2037 pts with a variety of solid tumors from 16 trials were included for analysis.
- Overall incidence of all-grade skin rash was 88.2%, with 11.3% being high-grade (grade 3 or above).
- Overall incidence of all-grade acne-like skin rash was 81.6% with 6.5% being high-grade.
- Pts with CRC exhibited a significantly higher incidence of high-grade skin rash (12.6%) than those with non-CRC (6.6%) with a risk ratio of 1.9.
- From randomized controlled studies, pts who received cetuximab had a significantly increased risk of developing high-grade skin rash vs controls.
Related Articles
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
Investigational New Drugs, 10/28/09
Relevance Score: 82%
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Relevance Score: 71%
Cetuximab-based treatment of metastatic anal cancer: Correlation of response with KRAS mutational status
Oncology (Karger), 11/18/09
Relevance Score: 68%
Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab
American Journal of Clinical Oncology, 10/09/09
Relevance Score: 68%
Underarm rash worsens with OTC treatment
JAAPA, 10/15/09
Relevance Score: 66%
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
EORTC Elderly Task Force experts opinion for the treatment of colon cancer in older patients
Cancer Treatment Reviews, 12/04/09
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer
Annals of Oncology, 12/04/09
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
Annals of Oncology, 12/04/09
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
BMC Cancer, 12/04/09
Predictors of Competing Mortality in Advanced Head and Neck Cancer
Journal of Clinical Oncology, 12/04/09
Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma
Journal of Cancer Research & Clinical Oncology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Immunoglobulin G Fc Receptor FcgammaRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
Journal of Clinical Oncology, 12/04/09
Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
Journal of Clinical Oncology, 12/04/09
Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver
The Oncologist, 12/03/09
Sponsor
Article Search
Sponsor
Sponsor